Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    An Enquiry

    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Zidesamtinib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Nuvalent Presents Neladalkib Data in Advanced NSCLC at 2026 ASCO
    Nuvalent Presents Neladalkib Data in Advanced NSCLC at 2026 ASCO

    21 Apr 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/nuvalent-to-present-pivotal-data-from-alkove-1-trial-of-neladalkib-in-tki-pre-treated-advanced-alk-positive-nsclc-at-the-2026-american-society-of-clinical-oncology-annual-meeting-302748865.html

    PR NEWSWIRE
    21 Apr 2026
    Share Share
    Nuvalent To Unveil Zidesamtinib Data At AACR 2026 Meeting
    Nuvalent To Unveil Zidesamtinib Data At AACR 2026 Meeting

    18 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/nuvalent-to-present-new-preclinical-and-clinical-data-for-zidesamtinib-an-investigational-ros1-selective-inhibitor-at-aacr-annual-meeting-2026-302716553.html

    PR NEWSWIRE
    18 Mar 2026
    Share Share
    Nuvalent Advances Ontarget 2026 Plan, Highlights Key Milestones
    Nuvalent Advances Ontarget 2026 Plan, Highlights Key Milestones

    12 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/nuvalent-announces-ontarget-2026-operating-plan-progress-and-outlines-key-anticipated-2026-milestones-302658102.html

    PR NEWSWIRE
    12 Jan 2026
    Share Share
    Nuvalent's Zidesamtinib NDA Accepted By FDA For Ros1+ NSCLC
    Nuvalent's Zidesamtinib NDA Accepted By FDA For Ros1+ NSCLC

    20 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/nuvalent-announces-fda-acceptance-of-new-drug-application-for-zidesamtinib-for-the-treatment-of-tki-pre-treated-patients-with-advanced-ros1-positive-nsclc-302620883.html

    PR NEWSWIRE
    20 Nov 2025
    Share Share
    Nuvalent To Present Patient-Reported Outcomes From Zidesamtinib
    Nuvalent To Present Patient-Reported Outcomes From Zidesamtinib

    05 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/nuvalent-to-present-patient-reported-outcomes-data-from-arros-1-trial-of-ros1-selective-inhibitor-zidesamtinib-at-2025-iaslc-asco-north-america-conference-on-lung-cancer-302604748.html

    PR NEWSWIRE
    05 Nov 2025
    Share Share
    Nuvalent's ARROS-1 Data on Zidesamtinib for ROS1-positive NSCLC
    Nuvalent's ARROS-1 Data on Zidesamtinib for ROS1-positive NSCLC

    13 Aug 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/nuvalent-to-present-pivotal-data-from-arros-1-clinical-trial-of-zidesamtinib-for-tki-pre-treated-patients-with-advanced-ros1-positive-nsclc-at-wclc-2025-presidential-symposium-302529250.html

    PR NEWSWIRE
    13 Aug 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.